FrancophonIA/ELRC3.0 huggingface dataset:
English: There was no significant difference between etoricoxib and diclofenac in the rate of complicated events.
Slovenian: Pri deležu zapletenih dogodkov razlika pri etorikoksibu in diklofenaku ni bila pomembna.
English: Whereas
Slovenian: etorikoksib
English: Take <ARCOXIA> Tablets by mouth once a day.
Slovenian: Tableto zdravila <ARCOXIA> pogoltnite enkrat na dan. Tablete zdravila <ARCOXIA> lahko jemljete skupaj s hrano ali brez nje.
English: Czech Rep.
Slovenian: Paço d' Arcos
English: <ARCOXIA (see Annex 1)> 60 mg film-coated tablets <ARCOXIA (see Annex 1)> 90 mg film-coated tablets <ARCOXIA (see Annex 1)> 120 mg film-coated tablets [See Annex I - To be completed nationally]
Slovenian: <ARCOXIA (Glejte Dodatek I)> 60 mg filmsko obložene tablete <ARCOXIA (Glejte Dodatek I)> 90 mg filmsko obložene tablete <ARCOXIA (Glejte Dodatek I)> 120 mg filmsko obložene tablete [Glejte Dodatek I - Izpolni država članica]
English: <ARCOXIA (see Annex 1)> 30 mg film-coated tablets <ARCOXIA (see Annex 1)> 60 mg film-coated tablets <ARCOXIA (see Annex 1)> 90 mg film-coated tablets <ARCOXIA (see Annex 1)> 120 mg film-coated tablets [See Annex 1- To be completed nationally]
Slovenian: <ARCOXIA (Glejte Dodatek I)> 30 mg filmsko obložene tablete <ARCOXIA (Glejte Dodatek I)> 60 mg filmsko obložene tablete <ARCOXIA (Glejte Dodatek I)> 90 mg filmsko obložene tablete <ARCOXIA (Glejte Dodatek I)> 120 mg filmsko obložene tablete
English: <ARCOXIA (see Annex 1)> 30 mg film-coated tablets <ARCOXIA (see Annex 1)> 60 mg film-coated tablets <ARCOXIA (see Annex 1)> 90 mg film-coated tablets <ARCOXIA (see Annex 1)> 120 mg film-coated tablets [See Annex I - To be completed nationally]
Slovenian: <ARCOXIA (glejte Dodatek I)> 30 mg filmsko obložene tablete <ARCOXIA (glejte Dodatek I)> 60 mg filmsko obložene tablete <ARCOXIA (glejte Dodatek I)> 90 mg filmsko obložene tablete <ARCOXIA (glejte Dodatek I)> 120 mg filmsko obložene tablete [Glejte Dodatek I - Izpolni država članica]
English: Uncommon: anxiety, depression, mental acuity decreased.
Slovenian: Občasne: povečanje ali zmanjšanje apetita, povečanje telesne teže Psihiatrične motnje:
English: BEFORE YOU TAKE <ARCOXIA>
Slovenian: KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO <ARCOXIA>
English: Common: ALT increased, AST increased.
Slovenian: Pogoste: zvišana ALT, zvišana AST
English: • You have a history of stroke or mini stroke.
Slovenian: • ste kdaj doživeli možgansko kap ali malo možgansko kap.
English: Always take <ARCOXIA> exactly as your doctor has told you.
Slovenian: Pri jemanju zdravila <ARCOXIA> natančno upoštevajte zdravnikova navodila.
English: Merck Sharp & Dohme B.V. Waarderweg P.O Box 581
Slovenian: Waarderweg 39, P.O Box 581
English: Further safety data should be provided by ongoing studies.
Slovenian: Potekajoče študije bodo morale zagotoviti nadaljnje podatke o varnosti.
English: What measures are being taken to ensure the safe and effective use of Afstyla?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Afstyla?
English: The second study involved 83 patients below 12 years of age.
Slovenian: Druga študija je vključevala 83 bolnikov, mlajših od 12 let.
English: The full EPAR for Afstyla can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Afstyla je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Afstyla
Slovenian: Druge informacije o zdravilu Afstyla
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Afstyla's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Afstyla večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: This is a summary of the European public assessment report (EPAR) for Afstyla.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Afstyla.
English: Afstyla lonoctocog alfa
Slovenian: Afstyla lonoktokog alfa
English: The first study involved 173 patients aged 12 years and above.
Slovenian: Prva študija je vključevala 173 bolnikov, starih 12 let in več.
English: What is Afstyla and what is it used for?
Slovenian: Kaj je zdravilo Afstyla in za kaj se uporablja?
English: They may include: angioedema (swelling of tissues under the skin), burning and stinging at the injection site, chills, flushing, itchy rash over the whole body, headache, hives, hypotension (low blood pressure), lethargy, nausea (feeling sick), restlessness, tachycardia (rapid heartbeat), tightness of the chest, tingling, vomiting and wheezing.
Slovenian: Te lahko vključujejo angioedem (otekanje podkožnega tkiva), pekoč občutek in zbadanje na mestu injiciranja, mrzlico, rdečico, srbeč izpuščaj po vsem telesu, glavobol, koprivnico, hipotenzijo (nizek krvni tlak), letargijo, navzejo (slabost), nemir, tahikardijo (pospešen srčni utrip), stiskanje v prsih, mravljinčenje, bruhanje in piskanje v pljučih.
English: The active substance in Afstyla, lonoctocog alfa, is a shorter version of human factor VIII that works in the body in the same way as human factor VIII.
Slovenian: Zdravilna učinkovina v zdravilu Afstyla, lonoktokog alfa, je krajša različica humanega faktorja VIII, ki deluje v telesu enako kot humani faktor VIII.
English: It is not intended to provide practical advice on how to use Afstyla.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: What benefits of Afstyla have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Afstyla izkazalo v študijah?
English: What are the risks associated with Afstyla?
Slovenian: Kakšna tveganja so povezana z zdravilom Afstyla?
English: Why is Afstyla approved?
Slovenian: Zakaj je bilo zdravilo Afstyla odobreno?
English: For more information about treatment with Afstyla, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Afstyla preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Among those patients who received Afstyla to prevent bleeding, an average of 1.14 bleeding episodes per year was recorded for each patient which was lower than the 19.64 episodes per year in patients not receiving Afstyla for prevention.
Slovenian: Med bolniki, ki so prejemali zdravilo Afstyla za preprečevanje krvavitev, so zabeležili v povprečju 1,14 epizode krvavitve na leto za vsakega bolnika, kar je bilo nižje od 19,64 epizode na leto pri bolnikih, ki niso prejemali zdravila Afstyla za preprečevanje krvavitev.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Afstyla have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Afstyla upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: Regarding safety, the reported side effects are in line with those expected for a factor VIII product, although hypersensitivity reactions occurred more frequently with Afstyla.
Slovenian: Glede varnosti so neželeni učinki, o katerih so poročali, v skladu s pričakovanimi za zdravilo s faktorjem VIII, čeprav so se preobčutljivostne reakcije pojavile pogosteje pri zdravilu Afstyla.
English: The dose and frequency of the injections depend on whether Afstyla is used to treat or prevent bleeding, the severity of the patient's factor VIII deficiency, the extent and location of the bleeding and the patient's condition and bodyweight.
Slovenian: Odmerek in pogostnost injiciranja sta odvisna od tega, ali se zdravilo Afstyla uporablja za zdravljenje ali preprečevanje krvavitve, od resnosti bolnikovega pomanjkanja faktorja VIII, obsega in mesta krvavitve ter bolnikovega stanja in telesne mase.
English: A total of 848 bleeding episodes were recorded during the study, 94% of which resolved with one or two injections of Afstyla.
Slovenian: Med študijo so zabeležili skupno 848 epizod krvavitev, med katerimi so 94 % epizod krvavitev obvladali z eno ali dvema injekcijama zdravila Afstyla.
English: Among those patients who received Afstyla to prevent bleeding, the average number of bleeding episodes per year was 2.30 for patients receiving Afstyla three times a week, and 4.37 for those receiving Afstyla twice a week.
Slovenian: Med bolniki, ki so prejemali zdravilo Afstyla za preprečevanje krvavitev, je bilo povprečno število epizod krvavitev na leto 2,30 za bolnike, ki so prejemali zdravilo Afstyla trikrat na teden, in 4,37 za bolnike, ki so prejemali zdravilo Afstyla dvakrat na teden.
English: Hypersensitivity (allergic) reactions are common with Afstyla, affecting up to 1 in 10 people.
Slovenian: Preobčutljivostne (alergijske) reakcije so pogoste pri zdravilu Afstyla in se lahko pojavijo pri največ 1 bolniku od 10.
English: Afstyla has been shown to be effective at preventing and treating bleeding episodes in two main studies in patients with severe haemophilia A who were previously treated with other factor VIII products.
Slovenian: Zdravilo Afstyla se je izkazalo za učinkovito pri preprečevanju in zdravljenju epizod krvavitev v dveh glavnih študijah pri bolnikih s hudo hemofilijo A, ki so bili predhodno zdravljeni z drugimi zdravili s faktorjem VIII.
English: In the 16 surgical procedures that occurred during the study, Afstyla was rated as ‘excellent' or ‘good' in preventing bleeding episodes when used two to three times a week.
Slovenian: Pri 16 kirurških posegih, ki so jih opravili med študijo, je bilo zdravilo Afstyla ocenjeno kot „odlično“ ali „dobro“ pri preprečevanju epizod krvavitev, če se je uporabilo dva- do trikrat na teden.
English: Afstyla is available as a powder and solvent used to make a solution for injection.
Slovenian: Zdravilo Afstyla je na voljo kot prašek in vehikel za pripravo raztopine za injiciranje.
English: It contains the active substance lonoctocog alfa.
Slovenian: Vsebuje zdravilno učinkovino lonoktokog alfa.
English: Afstyla must not be used in patients with known allergy to hamster proteins.
Slovenian: Zdravilo Afstyla se ne sme uporabljati pri bolnikih z znano alergijo na beljakovine hrčka.
English: Afstyla can only be obtained with a prescription and treatment should be under the supervision of a doctor who has experience in the treatment of haemophilia.
Slovenian: Predpisovanje in izdaja zdravila Afstyla je le na recept, zdravljenje z njim pa mora biti pod nadzorom zdravnika z izkušnjami pri zdravljenju hemofilije.
English: Afstyla has been shown to be effective in both preventing and treating bleeding episodes.
Slovenian: Zdravilo Afstyla se je izkazalo za učinkovito pri preprečevanju in zdravljenju epizod krvavitev.
English: There is also a risk with factor VIII medicines that some patients will develop inhibitors (antibodies) against factor VIII, causing the medicine to stop working and resulting in a loss of bleeding control.
Slovenian: Pri zdravilih s faktorjem VIII obstaja tudi tveganje, da se bodo pri nekaterih bolnikih pojavili zaviralci (protitelesa) proti faktorju VIII, ki bodo izničili njegovo delovanje ter tako povzročili izgubo nadzora nad krvavitvijo.
English: Afstyla was rated as ‘excellent' or ‘good' at treating 96% of the 347 bleeding episodes recorded during the study; 96% of bleeding episodes resolved with one or two injections of Afstyla.
Slovenian: Zdravilo Afstyla je bilo ocenjeno kot „odlično“ ali „dobro“ pri zdravljenju 96 % od 347 epizod krvavitev, ki so jih zabeležili med študijo; 96 % epizod krvavitev je bilo obvladanih z eno ali dvema injekcijama zdravila Afstyla.
English: Afstyla was rated as ‘excellent' or ‘good' at treating 92% of the bleeding episodes.
Slovenian: Zdravilo Afstyla je bilo ocenjeno kot „odlično“ ali „dobro“ pri zdravljenju 92 % epizod krvavitev.
English: For practical information about using Afstyla, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Afstyla naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Afstyla is a medicine used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of a clotting protein called factor VIII).
Slovenian: Zdravilo Afstyla se uporablja za zdravljenje in preprečevanje krvavitev pri bolnikih s hemofilijo A (prirojeno motnjo strjevanja krvi zaradi pomanjkanja koagulacijske beljakovine, imenovane faktor VIII).
English: How does Afstyla work?
Slovenian: Kako zdravilo Afstyla deluje?
English: How is Afstyla used?
Slovenian: Kako se zdravilo Afstyla uporablja?
English: 10 March 2011
Slovenian: 10. marec 2011
English: The European Commission issued a decision on this opinion on 10 March 2011.
Slovenian: Evropska komisija je odločbo v zvezi s tem mnenjem izdala dne 10. marca 2011.
English: 4.1 Therapeutic indications
Slovenian: 4. 1 Terapevtske indikacije
English: The CHMP agreed on the following indications:
Slovenian: CHMP je potrdil naslednje indikacije:
English: As a result, the antibiotic stays in the body and can work for longer.
Slovenian: Zato antibiotik ostane v telesu dlje in lahko deluje dalj časa.
English: concerned Member States could not agree on the indications and on the recommendation for children under three years of age.
Slovenian: Zadevne države članice se niso strinjale o indikacijah in priporočilu za otroke, mlajše od treh let.
English: Why was Tienam reviewed?
Slovenian: Zakaj je bilo zdravilo Tienam pregledano?
English: The company that markets these medicines is Merck, Sharp & Dohme.
Slovenian: Družba, ki trži ta zdravila, je Merck, Sharp & Dohme.
English: During a decentralised procedure, the application submitted by the company is assessed by one Member State (the ‘reference Member State', in this instance the Netherlands), with a view of granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States').
Slovenian: V decentraliziranem postopku predloženo vlogo družbe oceni ena država članica („referenčna država članica“, v tem primeru Nizozemska) z namenom odobritve dovoljenja za promet z zdravilom, ki bo veljavno v tej državi in v vseh drugih državah članicah („zadevne države članice“).
English: The Committee also recommended harmonised wordings in other areas such as contra-indications, warnings and side effects.
Slovenian: Odbor je priporočil tudi uskladitev besedila na drugih področjih, kot so na primer kontraindikacije, opozorila in neželeni učinki.
English: • treatment of bacteraemia (bacteria in the blood) that is associated with or suspected to be associated with the infections listed above.
Slovenian: • zdravljenje bakteriemije (bakterije v krvi), ki je povezana ali naj bi bila povezana z navedenimi okužbami.
English: The medicine is available in all EU Member States under the trade name Tienam, as well under other trade names: Conet, Imipem, Primaxin, Tenacid and Zienam.
Slovenian: Zdravilo je na voljo v vseh državah članicah EU pod tržnim imenom Tienam in pod drugimi tržnimi imeni: Conet, Imipem, Primaxin, Tenacid in Zienam.
English: A company applied in the Netherlands for a generic version of Tienam in a decentralised procedure involving 16 Member States.
Slovenian: Družba je na Nizozemskem vložila vlogo za generično različico zdravila Tienam po decentraliziranem postopku, v katerega je bilo vključenih 16 držav članic.
English: On 18 May 2009, the Dutch medicines regulatory agency referred the matter to the CHMP in order to harmonise the marketing authorisations for Tienam in the EU.
Slovenian: Nizozemska regulativna agencija je dne 18. maja 2009 zadevo napotila na CHMP za uskladitev dovoljenj za promet z zdravilom Tienam v EU.
English: The CHMP also removed the use of Tienam in the prevention of infections.
Slovenian: CHMP je odstranil tudi navedbo za uporabo zdravila Tienam pri preprečevanju okužb.
English: For children, the CHMP recommended a harmonised dosage in children over one year of age, and made no dosage recommendations for children under one year of age because of a lack of data for this age group.
Slovenian: CHMP je priporočil usklajeni odmerek za otroke, starejše od enega leta, za otroke, mlajše od enega leta, pa CHMP zaradi pomanjkanja podatkov za to starostno skupino ni dal nobenega priporočila glede odmerka.
English: The European Medicines Agency has completed a review of Tienam.
Slovenian: Evropska agencija za zdravila je zaključila pregled zdravila Tienam.
English: Tienam is an antibiotic used in complicated infections, generally in hospital.
Slovenian: Zdravilo Tienam je antibiotik, ki se uporablja za komplicirane okužbe, in sicer predvsem v bolnišnicah.
English: What is Tienam?
Slovenian: Kaj je zdravilo Tienam?
English: 4.2 Posology and method of administration
Slovenian: 4. 2 Odmerjanje in način uporabe
English: It can also be used in patients whose immune system is weakened when they have a fever.
Slovenian: Uporablja se lahko tudi pri bolnikih z oslabljenim imunskim sistemom zaradi povišane telesne temperature.
English: • severe pneumonia including hospital and ventilator-associated pneumonia,
Slovenian: • huda pljučnica, vključno z bolnišnično in z ventilatorji povezano pljučnico,
English: The CHMP harmonised the posology (the dose and frequency of dosing) in adults.
Slovenian: CHMP je uskladil odmerjanje (odmerek in pogostnost odmerjanja) pri odraslih.
English: The CHMP recommended that Tienam should not be used in some indications, such as meningitis, osteomyelitis (infection of the bones) and lung infection in cystic fibrosis patients.
Slovenian: CHMP je priporočil, da se zdravilo Tienam ne sme uporabljati za nekatere indikacije, kot so meningitis, osteomielitis (okužba kosti) in okužbo pljuč pri bolnikih s cistično fibrozo.
English: It has been used to treat infections of the lungs, the urinary tract (structures that carry urine), the abdomen, skin and the reproductive system.
Slovenian: Uporablja se za zdravljenje okužb pljuč, sečil (organov, ki prenašajo urin), trebuha, kože in reproduktivnega sistema.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Tienam in the European Union (EU).
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri Agenciji je zaključil, da je treba v Evropski uniji (EU) uskladiti podatke o predpisovanju zdravila Tienam.
English: The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU.
Slovenian: CHMP je ob upoštevanju predloženih podatkov in znanstvenih razprav v Odboru menil, da je treba povzetke glavnih značilnosti zdravila, označevanje in navodila za uporabo uskladiti v celotni EU.
English: When Tienam is absorbed in the body, the imipenem component kills the bacteria that are causing the infection, while the cilastatin component blocks the dehypropeptidase enzyme in the kidney that normally breaks down imipenem.
Slovenian: Pri absorpciji zdravila Tienam v telo, imipenem uniči bakterije, ki povzročajo okužbo, medtem ko cilastatin zavira encim dehidropeptidaze v ledvicah, ki običajno razkraja imipenem.
English: • complicated intra-abdominal infections,
Slovenian: • zapletene intraabdominalne okužbe,
English: Tienam contains two active substances: imipenem, which is an antibiotic belonging to the carbapenem family, and cilastatin, which is a ‘dehydropeptidase inhibitor'.
Slovenian: Zdravilo Tienam vsebuje dve zdravilni učinkovini: imipenem, antibiotik, ki sodi v družino karbapenemov, in cilastatin, „zaviralec dehidropeptidaze“.
English: While this process was ongoing, divergences across Member States were noted in the way Tienam can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets.
Slovenian: Med potekom tega postopka so bile med državami članicami opazne razlike glede uporabe zdravila Tienam, kar se je odražalo v razlikah med povzetki glavnih značilnosti zdravila, označevanju in navodilih za uporabo.
English: • use for fever in neutropenic patients when infection is suspected,
Slovenian: • uporaba pri povišani telesni temperaturi pri nevtropeničnih bolnikih pri sumu okužbe,
English: • complicated skin and soft-tissue infections,
Slovenian: • zapletene okužbe kože in mehkih tkiv,
English: • intra- and post-partum infections,
Slovenian: • med- in poporodne okužbe,
English: MA (EU) Number (Invented) name Strength Pharmaceutical form
Slovenian: Številka (EU) dovoljenja za promet
English: Route of administration
Slovenian: Jakost Farmacevtska oblika Pot uporabe
English: ∗ 2.5 mg desloratadine/120 mg pseudoephedrine sulphate
Slovenian: ∗ 2,5 mg desloratadina/120 mg pseudoefedrinijevega sulfata
English: -1 Cell-associated live recombinant turkey herpes virus (rHVT/ND) expressing the fusion protein of Newcastle diseases virus D-26 lentogenic strain: 2,500 - 8,000 PFU*
Slovenian: -1 Celično vezan živ rekombinantni puranji herpes virus (rHTV/ND), ki izraža fuzijski protein virusa Newcastle bolezni D-26 lentogen sev: 2,500 - 8,000 PFU*
English: * PFU - plaque forming units.
Slovenian: * PFU - enote, ki tvorijo čep.
English: Strength Pharmaceutical form Target species
Slovenian: Jakost Farmacevtska oblika Ciljna živalska vrsta
English: Route of administration
Slovenian: Karenca
English: It is used for the treatment of the following diseases:
Slovenian: Uporablja se za zdravljenje naslednjih obolenj:
English: The usual recommended dose is 50 mg once a week.
Slovenian: Običajni priporočeni odmerek je 50 mg enkrat na teden.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Benepali on 14 January 2016.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Benepali, veljavno po vsej Evropski uniji, izdala 14. januarja 2016.
English: What measures are being taken to ensure the safe and effective use of Benepali?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Benepali?
English: This means that Benepali is highly similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU).
Slovenian: To pomeni, da je zelo podobno biološkemu zdravilu (t. i. „referenčnemu zdravilu“), ki je že odobreno v Evropski uniji (EU).
English: The full EPAR and risk management plan summary for Benepali can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Benepali sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Benepali.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Benepali.
English: It is not intended to provide practical advice on how to use Benepali.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: The main measure of effectiveness was the proportion of patients who achieved at least a 20% reduction in ACR scores (a measure of painful, swollen joints and other symptoms) after 24 weeks of treatment.
Slovenian: Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih je po 24 tednih zdravljenja prišlo do najmanj 20-odstotnega zmanjšanja vrednosti ACR (merilo za boleče, otekle sklepe in druge simptome).